Subependymal giant cell astrocytoma epidemiology and demographics
|
Subependymal giant cell astrocytoma Microchapters |
|
Differentiating Subependymal Giant Cell Astrocytoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Subependymal giant cell astrocytoma epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Subependymal giant cell astrocytoma epidemiology and demographics |
|
FDA on Subependymal giant cell astrocytoma epidemiology and demographics |
|
CDC on Subependymal giant cell astrocytoma epidemiology and demographics |
|
Subependymal giant cell astrocytoma epidemiology and demographics in the news |
|
Blogs on Subependymal giant cell astrocytoma epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Ifeoma Odukwe, M.D. [2], Sujit Routray, M.D. [3]
Overview
Subependymal giant cell astrocytoma is the most common central nervous system tumor in patients with tuberous sclerosis complex. Approximately 10-20% of patients with tuberous sclerosis develop subependymal giant cell astrocytoma. It is a disease that tends to commonly affect the pediatric population with males being more affected than females.
Epidemiology and Demographics
Incidence
- The incidence of subependymal giant cell astrocytoma is approximately 0.027 per 100,000 person-years.[1]
Prevalence
- Subependymal giant cell astrocytoma is the most common central nervous system tumor in patients with tuberous sclerosis complex.[2]
- Approximately 10-20% of patients with tuberous sclerosis develop subependymal giant cell astrocytoma.[3]
Age
- Subependymal giant cell astrocytoma is a disease that tends to affect the pediatric, adolescent, and young adult population.[4]
- The mean age at diagnosis is 13 years.[5]
- It commonly presents in the first two decades of life.[6]
- It becomes symptomatic, clinically and pathologically, between 8 to 19 years of age.[2]
Race
- There is no racial predilection to subependymal giant cell astrocytoma.
Gender
References
- ↑ Nguyen HS, Doan NB, Gelsomino M, Shabani S, Awad AJ, Best B; et al. (2018). "Subependymal Giant Cell Astrocytoma: A Surveillance, Epidemiology, and End Results Program-Based Analysis from 2004 to 2013". World Neurosurg. 118: e263–e268. doi:10.1016/j.wneu.2018.06.169. PMID 29966782.
- ↑ 2.0 2.1 2.2 Ouyang, Taohui; Zhang, Na; Benjamin, Thomas; Wang, Long; Jiao, Jiantong; Zhao, Yiqing; Chen, Jian (2014). "Subependymal giant cell astrocytoma: current concepts, management, and future directions". Child's Nervous System. 30 (4): 561–570. doi:10.1007/s00381-014-2383-x. ISSN 0256-7040.
- ↑ Roth, Jonathan; Roach, E. Steve; Bartels, Ute; Jóźwiak, Sergiusz; Koenig, Mary Kay; Weiner, Howard L.; Franz, David N.; Wang, Henry Z. (2013). "Subependymal Giant Cell Astrocytoma: Diagnosis, Screening, and Treatment. Recommendations From the International Tuberous Sclerosis Complex Consensus Conference 2012". Pediatric Neurology. 49 (6): 439–444. doi:10.1016/j.pediatrneurol.2013.08.017. ISSN 0887-8994.
- ↑ 4.0 4.1 Campen CJ, Porter BE (2011). "Subependymal Giant Cell Astrocytoma (SEGA) Treatment Update". Curr Treat Options Neurol. 13 (4): 380–5. doi:10.1007/s11940-011-0123-z. PMC 3130084. PMID 21465222.
- ↑ Nabbout, R; Santos, M; Rolland, Y; Delalande, O; Dulac, O; Chiron, C (1999). "Early diagnosis of subependymal giant cell astrocytoma in children with tuberous sclerosis". Journal of Neurology, Neurosurgery & Psychiatry. 66 (3): 370–375. doi:10.1136/jnnp.66.3.370. ISSN 0022-3050.
- ↑ Stein JR, Reidman DA (2016). "Imaging Manifestations of a Subependymal Giant Cell Astrocytoma in Tuberous Sclerosis". Case Rep Radiol. 2016: 3750450. doi:10.1155/2016/3750450. PMC 4752974. PMID 26942030.
- ↑ Sun P, Kohrman M, Liu J, Guo A, Rogerio J, Krueger D (2012). "Outcomes of resecting subependymal giant cell astrocytoma (SEGA) among patients with SEGA-related tuberous sclerosis complex: a national claims database analysis". Curr Med Res Opin. 28 (4): 657–63. doi:10.1185/03007995.2012.658907. PMID 22375958.